Theravance IPO Would Fund Phase III Telavancin Antibiotic Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase I data for telavancin indicates non-inferiority to standard of care therapy. Theravance also has a broad collaborative agreement with GSK for long-acting beta-2 agonists for the treatment of COPD. Former Merck CEO Roy Vagelos is chairman of Theravance.
You may also be interested in...
GSK/Theravance Target 2008 Phase III Start For Next-Gen Bronchodilators
Two compounds stemming from the collaboration given once daily were equivalent to salmeterol twice daily in Phase IIb clinical studies.
GSK/Theravance Target 2008 Phase III Start For Next-Gen Bronchodilators
Two compounds stemming from the collaboration given once daily were equivalent to salmeterol twice daily in Phase IIb clinical studies.
Theravance’s First NDA Is Antibiotic Telavancin
Firm is seeking approval of telavancin for complicated skin and skin structure infections caused by Gram-positive bacteria.